Skip to content

A Study to Evaluate of Cosmetic Benefit of a Moisturising Cream in People With Blemish Prone Skin

A Randomized, Parallel-group, Evaluator-blind, No-treatment and Positive Controlled, Single-site, Proof of Concept Clinical Study to Evaluate the Cosmetic Benefit Provided by 8 Weeks of Twice-daily Topical Application of a Developmental Moisturizing Cream With Niacinamide in Healthy Subjects With Sensitive, Oily, Blemish-prone Skin

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03093181
Enrollment
157
Registered
2017-03-28
Start date
2017-04-04
Completion date
2017-08-28
Last updated
2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin Care

Brief summary

This study is designed to evaluate the cosmetic benefit provided by twice daily application of a developmental moisturising cream with niacinamide for 8 weeks in healthy female participants with sensitive, oily, blemish-prone skin.

Detailed description

This study broadly consists of two phases: screening / washout phase (5-7 day) followed by treatment phase (approximately of 8 weeks). Participants will be asked to return to the study site 1 week, 4 weeks and 8 weeks after their randomisation visit for instrumental measurements and clinical assessments.

Interventions

OTHERWashout / Standard Cleanser

Participants will apply standard cleanser (Simple Kind to Skin Moisturising Facial Wash) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the standard cleanser in a 5-7 day washout period and during the test phase of the study

OTHERTest product

Participants will apply 0.6 gram (g) of Test product (Moisturising Cream with Niacinamide) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the test product during the test phase of the study.

OTHERPositive control cleanser

Participants will apply positive control cleanser (Neutrogena Visibly Clear Spot Clearing Facial Wash) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the positive control cleanser during the test phase of the study.

OTHERPositive control moisturiser

Participants will apply 0.6 g of positive control moisturiser (Vivatinell Acnecinamide Gel Cream) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the positive control moisturiser during the test phase of the study.

Sponsors

GlaxoSmithKline
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Demonstrates understanding of the study procedures, restrictions and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form * Good general and mental health with, in the opinion of the investigator or medically qualified designee no clinically significant and relevant abnormalities in medical history or upon physical examination * Willingness to actively participate in the study and to attend all scheduled visits * Minimum of 10 and maximum of 25 blemishes (papules and pustules) at Visit 1 and a minimum of 8 blemishes (papules and pustules) at Visit 2 * Fitzpatrick photo-type I-V * Sebumeter score of \>66 µg / cm2 at the forehead * Females of childbearing potential who are, in the opinion of the investigator, practicing a reliable method of contraception. Adequate contraception is defined as abstinence, oral contraceptive, either combined or progestogen alone OR injectable progestogen OR implants of levonorgestrel OR estrogenic vaginal ring OR percutaneous contraceptive patches OR intrauterine device or intrauterine system OR double barrier method (condom or occlusive cap \[diaphragm or cervical vault caps\] plus spermicidal agent \[foam, gel, film, cream, suppository\]) OR male partner sterilization prior to the female participant's entry into the study, and this male is the sole partner for that participant * Cleanses their face at least once a day

Exclusion criteria

* Women who are known to be pregnant or who are intending to become pregnant over the duration of the study * Women who are breast-feeding * Medical history of using a medicated acne treatment (e.g. Benzoyl Peroxide, Clindamycin, isotretinoin) within the last 12 months * Change in contraception within the last 3 months * Active skin disease in the test area * Medical history of dysplastic nevi or melanoma on the face * Moles, cysts, tattoos, scars, irritated skin, hairs, etc. at the test area that could influence the investigation * Systemic therapy with immuno-suppressive drugs (e.g. corticosteroids) and/or antihistamines within 7 days prior to the start of the study and/or throughout the entire course of the study * Systemic use of anti-microbials within the last month * Systemic use of over-the-counter (OTC) analgesics or anti-inflammatory drugs 24 hours prior to dosing at the first assessment visit * One of the following illnesses that might require regular systemic medication: Insulin-dependent diabetes, cancer * One of the following illnesses if not medicated: Asthma, hypertension * Medical history of abnormal response to sunlight * History of mental illness * Medically diagnosed acne vulgaris, acne conglobate, fulminans, secondary acne (drug induced acne) or any acne requiring systemic or topical treatment * No aesthetic, cosmetic or dermatological treatment in the treatment area (face) within the last month * No intense sun exposure, Ultraviolet-treatments or tanning salon visit within the last 2 weeks * Known or suspected intolerance, allergy or hypersensitivity to study materials (or closely related compounds) or any of their stated ingredients * History of allergies to cosmetic products or medicated acne treatments * Participation in another clinical study (including cosmetic studies) or receipt of an investigational drug within 30 days of the screening visit * Previous participation in this study * Recent history (within the last 5 years) of alcohol or other substance abuse * An employee of the sponsor or the study site or members of their immediate family

Design outcomes

Primary

MeasureTime frameDescription
Change From Baseline in Corneometer Values at 8 Hours on Day 1At Baseline and Day 1A blinded, trained and qualified evaluator conducted instrumental measurements of skin moisturization.Measurement of skin moisturization was performed by the electrical capacitance method with a Corneometer CM 865. The measuring principle was based on changes in the capacitance of the measuring head, functioning as a condensator. Between the conductors of the probe an electrical field was built which allows the dielectricity of the stratum corneum to be measured. Because the dielectricity of the skin varies as a function of its water content.The range of hydration level was 0 (as dry as possible)\ 120 AU (Arbitrary Unit)(most moist possible).Higher Corneometer values are indicative of improved skin moisturization.

Secondary

MeasureTime frameDescription
Odds for Logistic Regression Analysis on Improvement Rating of Lay Person Assessment of Polarized and Non-polarized Images Week 8 Compared to BaselineAt Baseline and Week 8The baseline and week 8 photographs of all participants were displayed side by side on high resolution, color-calibrated display screen in room with neutral wall colors and standardized lighting and all practical efforts were made to minimize glare. The relative positioning (left and right) of baseline and week 8 photographs were blinded to evaluator and randomized. A technician used randomization schedule to display pair of images to lay evaluator. Lay evaluators judged magnitude of improvement in overall appearance of blemishes using the below criteria: Left=blemishes on left are more obvious than those on the right and Right=blemishes on right are more obvious than those on the left. Layperson ranked both left and right image as follows:1=Better;2=Worse. Odds was calculated from logistic regression including treatment and age stratum effects and exchangeable correlation. Odds=p/(1-p) where p was the probability of event that Week 8 was better than baseline.
ANOVA Analysis on Improvement Rating of Lay Person Assessment of Polarized and Non-polarized Images Week 8 Compared to BaselineAt Baseline and Week 8Baseline and Week 8 photographs of all participants were displayed side by side on high resolution, color-calibrated display screen in room with neutral wall colors and standardized lighting with minimized glare. Relative positioning (left and right) of baseline and Week 8 photographs were blinded to evaluator and randomized. Lay evaluators ranked magnitude of improvement in overall appearance of blemishes using below criteria: Left=blemishes on left are more obvious than those on right; Right=blemishes on right are more obvious than those on left. Lay evaluator ranking for each image pair was converted into a numerical score based on whether Baseline or Week 8 image was ranked better:0=Baseline image was better than Week 8 image,1=Week 8 image was better than Baseline image. Minimum score 0 corresponded to all baseline images being better than Week 8 images. Maximum score 1 corresponded to all Week 8 images being better than baseline images. Higher scores indicated better results.
Change From Baseline in Corneometer Values at 1 and 3 Hours on Day 1 and at Week 1, 4 and 8At Baseline, Day 1, Week 1, 4 and 8A blinded, trained and qualified evaluator conducted instrumental measurements of skin moisturisation. Measurement of skin moisturisation was performed by the electrical capacitance method with a Corneometer CM 865. The measuring principle was based on changes in the capacitance of the measuring head, functioning as a condensator. Between the conductors of the probe an electrical field was built which allows the dielectricity of the stratum corneum to be measured. Because the dielectricity of the skin varies as a function of its water content. Higher Corneometer values are indicative of improved skin moisturisation.
Change From Baseline in Sebumeter Values at Week 1, 4 and 8At Baseline, Week 1, 4 and 8A treatment blinded, trained and qualified evaluator conducted instrumental measurements of skin sebum levels. Measurement of skin sebum levels was performed by with a Sebumeter SM 815. The measurement principle of the SM 815 is based on grease spot photometry. The translucent tape of the device is brought into contact with skin and becomes increasingly transparent in response to surface oil. The tape is inserted into the aperture of the device and its transparency measured by light transmission, with increased transmission signifying increased oiliness. The software outputs mass sebum levels as a function of area. Sebumeter measurements were taken in triplicate at the central forehead (above the eyebrows) with the participant lying horizontally, on their back.
Change From Baseline in Sebum Excretion Rate at Week 1, 4 and 8At Baseline, Week 1, 4 and 8The forehead of each participant was thoroughly cleansed by the investigator or designee using cotton pads saturated with 70% Isopropyl Alcohol and, after 5 minutes, the central area of the forehead above the eyebrows was measured in triplicate with a Sebumeter. The same area was measured in triplicate 90 minutes after cleansing. The sebum excretion rate was calculated by the difference in 90th minutes and 5th minute Sebumeter values.
Change From Baseline in Evaluator's Assessment of Total Blemish Count at Week 1, 4, and 8At Baseline, Week 1, 4 and 8A treatment blind, trained and qualified evaluator counted the total number of facial blemishes on the forehead, cheeks and chin of the participants.

Countries

Brazil

Participant flow

Recruitment details

All the participants were recruited from one center in Brazil.

Pre-assignment details

Out of 205 screened participants,157 participants were enrolled, and 132 participants were randomized. 25 enrolled subjects were not subsequently randomized. Out of 132 randomized participants,1 participant was misallocated to treatment (received no treatment instead of positive control).

Participants by arm

ArmCount
Test Product Regimen
Participants randomized to test product regimen used the standard cleanser and test product twice a day (morning and night). Morning and evening applications were separated by at least 8 hours. Participants applied the test product cream immediately after cleansing.
44
No Treatment Regimen
Participants randomized to the no treatment regimen used the standard cleanser (only) twice a day (morning and night). Morning and evening applications were separated by at least 8 hours.
45
Positive Control Regimen
Participants randomized to positive control regimen used the positive cleanser and positive control product twice a day (morning and night). Morning and evening applications were separated by at least 8 hours. Participants applied the positive control cream immediately after cleansing.
43
Total132

Withdrawals & dropouts

PeriodReasonFG000FG001FG002
Overall StudyAdverse Event010
Overall StudyOther (Not specified)100
Overall StudyOther (Protocol violation)001
Overall StudyWithdrawal by Subject212

Baseline characteristics

CharacteristicTotalTest Product RegimenNo Treatment RegimenPositive Control Regimen
Age, Continuous25.3 Years
STANDARD_DEVIATION 5.84
25.4 Years
STANDARD_DEVIATION 5.82
25.8 Years
STANDARD_DEVIATION 6.05
24.8 Years
STANDARD_DEVIATION 5.72
Race (NIH/OMB)
American Indian or Alaska Native
8 Participants3 Participants5 Participants0 Participants
Race (NIH/OMB)
Asian
1 Participants0 Participants0 Participants1 Participants
Race (NIH/OMB)
Black or African American
42 Participants14 Participants10 Participants18 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
81 Participants27 Participants30 Participants24 Participants
Sex: Female, Male
Female
132 Participants44 Participants45 Participants43 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 440 / 450 / 43
other
Total, other adverse events
1 / 442 / 455 / 43
serious
Total, serious adverse events
0 / 440 / 450 / 43

Outcome results

Primary

Change From Baseline in Corneometer Values at 8 Hours on Day 1

A blinded, trained and qualified evaluator conducted instrumental measurements of skin moisturization.Measurement of skin moisturization was performed by the electrical capacitance method with a Corneometer CM 865. The measuring principle was based on changes in the capacitance of the measuring head, functioning as a condensator. Between the conductors of the probe an electrical field was built which allows the dielectricity of the stratum corneum to be measured. Because the dielectricity of the skin varies as a function of its water content.The range of hydration level was 0 (as dry as possible)\ 120 AU (Arbitrary Unit)(most moist possible).Higher Corneometer values are indicative of improved skin moisturization.

Time frame: At Baseline and Day 1

Population: Intent to treat (ITT, N= 132) population included all participants who were randomized into the study and have at least one post-baseline measurement available.

ArmMeasureValue (MEAN)Dispersion
Test Product RegimenChange From Baseline in Corneometer Values at 8 Hours on Day 16.14 Arbitrary Corneometer unitStandard Deviation 6.442
No Treatment RegimenChange From Baseline in Corneometer Values at 8 Hours on Day 12.63 Arbitrary Corneometer unitStandard Deviation 5.602
Positive Control RegimenChange From Baseline in Corneometer Values at 8 Hours on Day 13.60 Arbitrary Corneometer unitStandard Deviation 7.86
p-value: 0.012895% CI: [0.68, 5.56]ANCOVA
p-value: 0.226295% CI: [-0.95, 3.96]ANCOVA
Secondary

ANOVA Analysis on Improvement Rating of Lay Person Assessment of Polarized and Non-polarized Images Week 8 Compared to Baseline

Baseline and Week 8 photographs of all participants were displayed side by side on high resolution, color-calibrated display screen in room with neutral wall colors and standardized lighting with minimized glare. Relative positioning (left and right) of baseline and Week 8 photographs were blinded to evaluator and randomized. Lay evaluators ranked magnitude of improvement in overall appearance of blemishes using below criteria: Left=blemishes on left are more obvious than those on right; Right=blemishes on right are more obvious than those on left. Lay evaluator ranking for each image pair was converted into a numerical score based on whether Baseline or Week 8 image was ranked better:0=Baseline image was better than Week 8 image,1=Week 8 image was better than Baseline image. Minimum score 0 corresponded to all baseline images being better than Week 8 images. Maximum score 1 corresponded to all Week 8 images being better than baseline images. Higher scores indicated better results.

Time frame: At Baseline and Week 8

Population: ITT (N= 132) population included all participants who were randomized into the study and have at least one post-baseline measurement available.

ArmMeasureGroupValue (LEAST_SQUARES_MEAN)Dispersion
Test Product RegimenANOVA Analysis on Improvement Rating of Lay Person Assessment of Polarized and Non-polarized Images Week 8 Compared to BaselineFor Polarised Image0.65 Score on scaleStandard Error 0.048
Test Product RegimenANOVA Analysis on Improvement Rating of Lay Person Assessment of Polarized and Non-polarized Images Week 8 Compared to BaselineFor Non-polarised Image0.67 Score on scaleStandard Error 0.047
No Treatment RegimenANOVA Analysis on Improvement Rating of Lay Person Assessment of Polarized and Non-polarized Images Week 8 Compared to BaselineFor Polarised Image0.50 Score on scaleStandard Error 0.047
No Treatment RegimenANOVA Analysis on Improvement Rating of Lay Person Assessment of Polarized and Non-polarized Images Week 8 Compared to BaselineFor Non-polarised Image0.52 Score on scaleStandard Error 0.046
Positive Control RegimenANOVA Analysis on Improvement Rating of Lay Person Assessment of Polarized and Non-polarized Images Week 8 Compared to BaselineFor Polarised Image0.51 Score on scaleStandard Error 0.047
Positive Control RegimenANOVA Analysis on Improvement Rating of Lay Person Assessment of Polarized and Non-polarized Images Week 8 Compared to BaselineFor Non-polarised Image0.51 Score on scaleStandard Error 0.047
Comparison: Analysis of Lay Person Assessment Polarised Image.p-value: 0.027995% CI: [0.02, 0.28]ANOVA
Comparison: Analysis of Lay Person Assessment Polarised Image.p-value: 0.888795% CI: [-0.12, 0.14]ANOVA
Comparison: Analysis of Lay Person Assessment Non-Polarised Image.p-value: 0.022495% CI: [0.02, 0.28]ANOVA
Comparison: Analysis of Lay Person Assessment Non-Polarised Image.p-value: 0.825395% CI: [-0.15, 0.12]ANOVA
Secondary

Change From Baseline in Corneometer Values at 1 and 3 Hours on Day 1 and at Week 1, 4 and 8

A blinded, trained and qualified evaluator conducted instrumental measurements of skin moisturisation. Measurement of skin moisturisation was performed by the electrical capacitance method with a Corneometer CM 865. The measuring principle was based on changes in the capacitance of the measuring head, functioning as a condensator. Between the conductors of the probe an electrical field was built which allows the dielectricity of the stratum corneum to be measured. Because the dielectricity of the skin varies as a function of its water content. Higher Corneometer values are indicative of improved skin moisturisation.

Time frame: At Baseline, Day 1, Week 1, 4 and 8

Population: ITT (N= 132) population included all participants who were randomized into the study and have at least one post-baseline measurement available.

ArmMeasureGroupValue (MEAN)Dispersion
Test Product RegimenChange From Baseline in Corneometer Values at 1 and 3 Hours on Day 1 and at Week 1, 4 and 8At 1 hour, Day 111.52 Arbitrary Corneometer unitStandard Deviation 8.264
Test Product RegimenChange From Baseline in Corneometer Values at 1 and 3 Hours on Day 1 and at Week 1, 4 and 8At Week 44.33 Arbitrary Corneometer unitStandard Deviation 8.935
Test Product RegimenChange From Baseline in Corneometer Values at 1 and 3 Hours on Day 1 and at Week 1, 4 and 8At Week 87.54 Arbitrary Corneometer unitStandard Deviation 11.994
Test Product RegimenChange From Baseline in Corneometer Values at 1 and 3 Hours on Day 1 and at Week 1, 4 and 8At 3 hour, Day 19.64 Arbitrary Corneometer unitStandard Deviation 5.986
Test Product RegimenChange From Baseline in Corneometer Values at 1 and 3 Hours on Day 1 and at Week 1, 4 and 8At Week 14.39 Arbitrary Corneometer unitStandard Deviation 10.549
No Treatment RegimenChange From Baseline in Corneometer Values at 1 and 3 Hours on Day 1 and at Week 1, 4 and 8At Week 10.06 Arbitrary Corneometer unitStandard Deviation 9.024
No Treatment RegimenChange From Baseline in Corneometer Values at 1 and 3 Hours on Day 1 and at Week 1, 4 and 8At 3 hour, Day 10.68 Arbitrary Corneometer unitStandard Deviation 5.029
No Treatment RegimenChange From Baseline in Corneometer Values at 1 and 3 Hours on Day 1 and at Week 1, 4 and 8At Week 43.16 Arbitrary Corneometer unitStandard Deviation 7.028
No Treatment RegimenChange From Baseline in Corneometer Values at 1 and 3 Hours on Day 1 and at Week 1, 4 and 8At 1 hour, Day 1-3.69 Arbitrary Corneometer unitStandard Deviation 6.15
No Treatment RegimenChange From Baseline in Corneometer Values at 1 and 3 Hours on Day 1 and at Week 1, 4 and 8At Week 83.32 Arbitrary Corneometer unitStandard Deviation 10.059
Positive Control RegimenChange From Baseline in Corneometer Values at 1 and 3 Hours on Day 1 and at Week 1, 4 and 8At 3 hour, Day 14.33 Arbitrary Corneometer unitStandard Deviation 7.913
Positive Control RegimenChange From Baseline in Corneometer Values at 1 and 3 Hours on Day 1 and at Week 1, 4 and 8At Week 82.51 Arbitrary Corneometer unitStandard Deviation 12.969
Positive Control RegimenChange From Baseline in Corneometer Values at 1 and 3 Hours on Day 1 and at Week 1, 4 and 8At 1 hour, Day 14.55 Arbitrary Corneometer unitStandard Deviation 8.055
Positive Control RegimenChange From Baseline in Corneometer Values at 1 and 3 Hours on Day 1 and at Week 1, 4 and 8At Week 41.04 Arbitrary Corneometer unitStandard Deviation 8.124
Positive Control RegimenChange From Baseline in Corneometer Values at 1 and 3 Hours on Day 1 and at Week 1, 4 and 8At Week 13.31 Arbitrary Corneometer unitStandard Deviation 11.027
Secondary

Change From Baseline in Evaluator's Assessment of Total Blemish Count at Week 1, 4, and 8

A treatment blind, trained and qualified evaluator counted the total number of facial blemishes on the forehead, cheeks and chin of the participants.

Time frame: At Baseline, Week 1, 4 and 8

Population: ITT (N= 132) population included all participants who were randomized into the study and have at least one post-baseline measurement available.

ArmMeasureGroupValue (MEAN)Dispersion
Test Product RegimenChange From Baseline in Evaluator's Assessment of Total Blemish Count at Week 1, 4, and 8At Week 4-3.86 Total Blemish CountStandard Deviation 3.143
Test Product RegimenChange From Baseline in Evaluator's Assessment of Total Blemish Count at Week 1, 4, and 8At Week 1-0.70 Total Blemish CountStandard Deviation 4.338
Test Product RegimenChange From Baseline in Evaluator's Assessment of Total Blemish Count at Week 1, 4, and 8At Week 8-5.68 Total Blemish CountStandard Deviation 3.889
No Treatment RegimenChange From Baseline in Evaluator's Assessment of Total Blemish Count at Week 1, 4, and 8At Week 4-2.76 Total Blemish CountStandard Deviation 4.154
No Treatment RegimenChange From Baseline in Evaluator's Assessment of Total Blemish Count at Week 1, 4, and 8At Week 1-1.05 Total Blemish CountStandard Deviation 3.331
No Treatment RegimenChange From Baseline in Evaluator's Assessment of Total Blemish Count at Week 1, 4, and 8At Week 8-3.79 Total Blemish CountStandard Deviation 3.626
Positive Control RegimenChange From Baseline in Evaluator's Assessment of Total Blemish Count at Week 1, 4, and 8At Week 1-0.93 Total Blemish CountStandard Deviation 3.46
Positive Control RegimenChange From Baseline in Evaluator's Assessment of Total Blemish Count at Week 1, 4, and 8At Week 8-5.12 Total Blemish CountStandard Deviation 4.507
Positive Control RegimenChange From Baseline in Evaluator's Assessment of Total Blemish Count at Week 1, 4, and 8At Week 4-4.00 Total Blemish CountStandard Deviation 4.461
Secondary

Change From Baseline in Sebumeter Values at Week 1, 4 and 8

A treatment blinded, trained and qualified evaluator conducted instrumental measurements of skin sebum levels. Measurement of skin sebum levels was performed by with a Sebumeter SM 815. The measurement principle of the SM 815 is based on grease spot photometry. The translucent tape of the device is brought into contact with skin and becomes increasingly transparent in response to surface oil. The tape is inserted into the aperture of the device and its transparency measured by light transmission, with increased transmission signifying increased oiliness. The software outputs mass sebum levels as a function of area. Sebumeter measurements were taken in triplicate at the central forehead (above the eyebrows) with the participant lying horizontally, on their back.

Time frame: At Baseline, Week 1, 4 and 8

Population: ITT (N= 132) population included all participants who were randomized into the study and have at least one post-baseline measurement available.

ArmMeasureGroupValue (MEAN)Dispersion
Test Product RegimenChange From Baseline in Sebumeter Values at Week 1, 4 and 8At Week 4-49.57 Micrograms (μg)/square centimeter (cm^2)Standard Deviation 128.821
Test Product RegimenChange From Baseline in Sebumeter Values at Week 1, 4 and 8At Week 1-54.98 Micrograms (μg)/square centimeter (cm^2)Standard Deviation 133.157
Test Product RegimenChange From Baseline in Sebumeter Values at Week 1, 4 and 8At Week 8-86.49 Micrograms (μg)/square centimeter (cm^2)Standard Deviation 118.708
No Treatment RegimenChange From Baseline in Sebumeter Values at Week 1, 4 and 8At Week 4-67.52 Micrograms (μg)/square centimeter (cm^2)Standard Deviation 139.278
No Treatment RegimenChange From Baseline in Sebumeter Values at Week 1, 4 and 8At Week 1-70.50 Micrograms (μg)/square centimeter (cm^2)Standard Deviation 131.654
No Treatment RegimenChange From Baseline in Sebumeter Values at Week 1, 4 and 8At Week 8-87.04 Micrograms (μg)/square centimeter (cm^2)Standard Deviation 114.207
Positive Control RegimenChange From Baseline in Sebumeter Values at Week 1, 4 and 8At Week 1-52.19 Micrograms (μg)/square centimeter (cm^2)Standard Deviation 116.797
Positive Control RegimenChange From Baseline in Sebumeter Values at Week 1, 4 and 8At Week 8-65.85 Micrograms (μg)/square centimeter (cm^2)Standard Deviation 111.936
Positive Control RegimenChange From Baseline in Sebumeter Values at Week 1, 4 and 8At Week 4-21.67 Micrograms (μg)/square centimeter (cm^2)Standard Deviation 114.17
Secondary

Change From Baseline in Sebum Excretion Rate at Week 1, 4 and 8

The forehead of each participant was thoroughly cleansed by the investigator or designee using cotton pads saturated with 70% Isopropyl Alcohol and, after 5 minutes, the central area of the forehead above the eyebrows was measured in triplicate with a Sebumeter. The same area was measured in triplicate 90 minutes after cleansing. The sebum excretion rate was calculated by the difference in 90th minutes and 5th minute Sebumeter values.

Time frame: At Baseline, Week 1, 4 and 8

Population: ITT (N= 132) population included all participants who were randomized into the study and have at least one post-baseline measurement available.

ArmMeasureGroupValue (MEAN)Dispersion
Test Product RegimenChange From Baseline in Sebum Excretion Rate at Week 1, 4 and 8At Week 430.49 μg/cm^2Standard Deviation 153.074
Test Product RegimenChange From Baseline in Sebum Excretion Rate at Week 1, 4 and 8At Week 120.36 μg/cm^2Standard Deviation 135.959
Test Product RegimenChange From Baseline in Sebum Excretion Rate at Week 1, 4 and 8At Week 838.04 μg/cm^2Standard Deviation 162.934
No Treatment RegimenChange From Baseline in Sebum Excretion Rate at Week 1, 4 and 8At Week 444.97 μg/cm^2Standard Deviation 125.342
No Treatment RegimenChange From Baseline in Sebum Excretion Rate at Week 1, 4 and 8At Week 138.72 μg/cm^2Standard Deviation 149.325
No Treatment RegimenChange From Baseline in Sebum Excretion Rate at Week 1, 4 and 8At Week 832.91 μg/cm^2Standard Deviation 148.784
Positive Control RegimenChange From Baseline in Sebum Excretion Rate at Week 1, 4 and 8At Week 166.73 μg/cm^2Standard Deviation 161.57
Positive Control RegimenChange From Baseline in Sebum Excretion Rate at Week 1, 4 and 8At Week 867.10 μg/cm^2Standard Deviation 112.039
Positive Control RegimenChange From Baseline in Sebum Excretion Rate at Week 1, 4 and 8At Week 453.17 μg/cm^2Standard Deviation 137.181
Secondary

Odds for Logistic Regression Analysis on Improvement Rating of Lay Person Assessment of Polarized and Non-polarized Images Week 8 Compared to Baseline

The baseline and week 8 photographs of all participants were displayed side by side on high resolution, color-calibrated display screen in room with neutral wall colors and standardized lighting and all practical efforts were made to minimize glare. The relative positioning (left and right) of baseline and week 8 photographs were blinded to evaluator and randomized. A technician used randomization schedule to display pair of images to lay evaluator. Lay evaluators judged magnitude of improvement in overall appearance of blemishes using the below criteria: Left=blemishes on left are more obvious than those on the right and Right=blemishes on right are more obvious than those on the left. Layperson ranked both left and right image as follows:1=Better;2=Worse. Odds was calculated from logistic regression including treatment and age stratum effects and exchangeable correlation. Odds=p/(1-p) where p was the probability of event that Week 8 was better than baseline.

Time frame: At Baseline and Week 8

Population: ITT (N= 132) population included all participants who were randomized into the study and have at least one post-baseline measurement available.

ArmMeasureGroupValue (NUMBER)
Test Product RegimenOdds for Logistic Regression Analysis on Improvement Rating of Lay Person Assessment of Polarized and Non-polarized Images Week 8 Compared to BaselineFor Polarised Image1.84 Odds
Test Product RegimenOdds for Logistic Regression Analysis on Improvement Rating of Lay Person Assessment of Polarized and Non-polarized Images Week 8 Compared to BaselineFor Non-polarised Image2.06 Odds
No Treatment RegimenOdds for Logistic Regression Analysis on Improvement Rating of Lay Person Assessment of Polarized and Non-polarized Images Week 8 Compared to BaselineFor Non-polarised Image1.08 Odds
No Treatment RegimenOdds for Logistic Regression Analysis on Improvement Rating of Lay Person Assessment of Polarized and Non-polarized Images Week 8 Compared to BaselineFor Polarised Image1.00 Odds
Positive Control RegimenOdds for Logistic Regression Analysis on Improvement Rating of Lay Person Assessment of Polarized and Non-polarized Images Week 8 Compared to BaselineFor Polarised Image1.04 Odds
Positive Control RegimenOdds for Logistic Regression Analysis on Improvement Rating of Lay Person Assessment of Polarized and Non-polarized Images Week 8 Compared to BaselineFor Non-polarised Image1.02 Odds
Comparison: Analysis of Lay Person Assessment Polarised Image.p-value: 0.024395% CI: [1.08, 3.15]Odds Ratio
Comparison: Analysis of Lay Person Assessment Polarised Image.p-value: 0.893195% CI: [0.61, 1.78]Odds Ratio
Comparison: Analysis of Lay Person Assessment Non-Polarised Image.p-value: 0.018195% CI: [1.12, 3.25]Odds Ratio
Comparison: Analysis of Lay Person Assessment Non-Polarised Image.p-value: 0.831995% CI: [0.55, 1.63]Odds Ratio

Source: ClinicalTrials.gov · Data processed: Feb 20, 2026